Johnson & Johnson vs Madrigal Pharmaceuticals, Inc.
JNJ vs MDGL — side-by-side comparison from reported financials. JNJ leads 6, MDGL leads 2 of 8 comparable metrics.
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
Madrigal Pharmaceuticals, Inc.
MDGL · Healthcare
$471.75-1.08%Strong
| Metric | JNJ | MDGL |
|---|---|---|
| Price | $261.79 | $471.75 |
| Market cap | $631B | $10.9B |
| Revenue (TTM) | $97.9B | $1.28B |
| Revenue growth | +5.6% | +149.0% |
| Net margin | 21.5% | -25.3% |
| Free cash flow | $22.2B | -$207M |
| Net cash (debt) | ($27.8B) | $644M |
| 1-year price return | +37.0% | +10.1% |
| P/E | 29.9 | — |
| P/E vs own history (cheap-side %) | 16% | — |
| Dividend yield | 2.00% | — |
| Return on equity | 26% | -57% |
| Altman Z-score | — | 7.49 |
| CV checks passed | 10 of 11 | 5 of 11 |
| Employees | 140,800 | 915 |
Full résumé-style profiles: JNJ CV · MDGL CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.